Mounjaro, a diabetes medication, is not currently approved or available for sale in India. As such, there is no established price for Mounjaro in the Indian market [1]. The drug's availability is contingent upon regulatory approvals from Indian health authorities [1].
When might Mounjaro become available in India?
The timeline for Mounjaro's potential introduction to India depends on several factors, including the submission of regulatory applications by the manufacturer and the subsequent review process by Indian health agencies [1]. Information regarding specific timelines for regulatory submissions or approvals in India is not publicly available at this time [1].
What is Mounjaro and how does it work?
Mounjaro (tirzepatide) is a novel medication for the treatment of type 2 diabetes [1]. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. By activating both receptors, tirzepatide helps to improve blood sugar control through multiple mechanisms, including stimulating insulin secretion, reducing glucagon secretion, and slowing gastric emptying [1].
Why isn't Mounjaro available in India yet?
The absence of Mounjaro in India is due to the standard regulatory process that all new medications must undergo. Before a drug can be marketed and sold in any country, it requires approval from that country's national health regulatory authority. This process involves submitting extensive data on the drug's safety, efficacy, and quality for review. Mounjaro has received approvals in other regions, such as the United States and Europe, but approval in India is still pending [1].
How does Mounjaro compare to other diabetes medications?
In regions where Mounjaro is approved, clinical trials have demonstrated its efficacy in lowering HbA1c levels and promoting weight loss, often showing greater reductions compared to some other diabetes medications [1]. However, direct comparisons with drugs available in India would depend on Mounjaro's eventual approval and the specific therapeutic classes of drugs used for diabetes management in the country [1].
What is the global price of Mounjaro?
The list price of Mounjaro in the United States is approximately $1,049.41 per month for a supply of four 5 mg pens [2]. This price does not reflect any insurance coverage or patient assistance programs [2]. Prices in other countries where the drug is approved may vary due to local market conditions, healthcare systems, and regulatory pricing frameworks [1][2].
What are the potential side effects of Mounjaro?
Common side effects associated with Mounjaro include nausea, vomiting, diarrhea, decreased appetite, and abdominal pain [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, and allergic reactions [1]. Patients considering Mounjaro should discuss potential risks and side effects with their healthcare provider [1].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/tirzepatide/price